Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anavex Life Sciences

8.95
+0.11001.24%
Post-market: 8.90-0.0500-0.56%19:03 EDT
Volume:350.84K
Turnover:3.11M
Market Cap:761.32M
PE:-16.20
High:8.99
Open:8.81
Low:8.70
Close:8.84
Loading ...

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Associated Press Finance
·
12 Feb

Anavex Life Sciences Corp - Q1 Net Loss $12.1 Million, $0.14 per Share

THOMSON REUTERS
·
12 Feb

Anavex Life Sciences Corp expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
10 Feb

Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’

Insider Monkey
·
31 Jan

Anavex put volume heavy and directionally bearish

TIPRANKS
·
29 Jan

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 Jan

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Jan

Anavex Life Sciences Announces Issuance of Blarcamesine (Anavex®2-73) Composition of Matter U.S. Patent Expanding Its Intellectual Property Portfolio

THOMSON REUTERS
·
27 Jan

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

Zacks
·
24 Jan

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Jan

New Strong Buy Stocks for January 21st

Zacks
·
21 Jan

Anavex Life Sciences Shares Rise After Positive Trial Results for Alzheimer's Treatment

Dow Jones
·
16 Jan

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
16 Jan

BRIEF-Anavex Life Sciences Announces Peer-Reviewed Publication Of Oral Blarcamesine Phase Iib/Iii Data In The Journal Of Prevention Of Alzheimer’S Disease

Reuters
·
15 Jan

Anavex announces peer-reviewed publication Phase IIb/III data on blarcamesine

TIPRANKS
·
15 Jan

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase Iib/Iii Data in the Journal of Prevention of Alzheimer’s Disease

THOMSON REUTERS
·
15 Jan

BRIEF-New Phase IIB/III Clinical Data Demonstrates Over Three Years Of Continuous Treatment With Oral Blarcamesine To Significantly Benefit Early Alzheimer’S Disease Patients

Reuters
·
13 Jan

New Phase Iib/Iii Clinical Data Demonstrates Over Three Years of Continuous Treatment With Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

THOMSON REUTERS
·
13 Jan

Anavex Life Sciences Corp: Blarcamesine Exhibited a Favorable Safety Profile With No Treatment-Related Deaths

THOMSON REUTERS
·
13 Jan

Anavex Life Sciences Corp: Topline Attention-Ad Trial: Patients Showed Improved Cognition and Function Over Three Years

THOMSON REUTERS
·
13 Jan